Related Experiment Video
Updated: Jul 14, 2025
A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
Morusin Inhibits RANKL-induced Osteoclastogenesis and Ovariectomized Osteoporosis
Cong Jin1, Jiewen Zheng1,2, Qichang Yang1,3
1Department of Orthopaedics, Shaoxing People's Hospital, Shaoxing, Zhejiang, 312000, China.
Background:
Postmenopausal osteoporosis (PMOP) is a classic type of osteoporosis that has gradually become a significant health problem worldwide. There is an urgent need for a safe alternative therapeutic agent considering the poor therapeutic strategies currently available for this disease. The roots and bark of the Morus australis tree (Moraceae) are used to make a traditional Chinese medicine known as "Morusin", and accumulating evidence has demonstrated its multiple activities, such as anti-inflammatory and anti-tumor effects.
Objective:
In this study, we aim to explore the effect of Morusin on mouse osteoclasts and its mechanism.
Methods:
In this study, we explored the inhibitory effects of Morusin on murine osteoclasts in vitro and its mechanism, and the protective effect of Morusin on an ovariectomy (OVX)-induced osteoporosis model in vivo.
Results:
The results showed that Morusin prevented OVX-induced bone loss and dramatically decreased RANKL-induced osteoclastogenesis. Morusin interfered with RANKL-activated NF- κB, MAPK, and PI3K/AKT signaling pathways. The expression of three master factors that control osteoclast differentiation, c-Fos, NFATc1, and c-Jun, was reduced by Morusin treatment. Collectively, in vitro results indicated that Morusin has a protective effect on OVX-induced bone loss in a mouse model.
Conclusion:
Our data provide encouraging evidence that Morusin may be an effective treatment for PMOP.
Insights
Morusin, derived from the Morus australis tree, shows promise in treating postmenopausal osteoporosis. This natural compound effectively inhibits bone loss and osteoclast formation in mouse models.
Area of Science:
- Pharmacology
- Osteoporosis Research
- Traditional Chinese Medicine
Background:
- Postmenopausal osteoporosis (PMOP) is a growing global health concern with limited therapeutic options.
- There is a critical need for safe and effective alternative treatments for PMOP.
- Morusin, a compound from *Morus australis*, exhibits various bioactivities, including anti-inflammatory and anti-tumor effects.
Purpose of the Study:
- To investigate the therapeutic potential of Morusin against postmenopausal osteoporosis.
- To elucidate the mechanism of Morusin's action on osteoclasts and bone metabolism.
Main Methods:
- Evaluated the inhibitory effects of Morusin on murine osteoclasts *in vitro*.
- Assessed the protective effects of Morusin in an ovariectomy (OVX)-induced osteoporosis mouse model *in vivo*.
- Analyzed the impact of Morusin on key signaling pathways (NF-κB, MAPK, PI3K/AKT) and osteoclast differentiation factors (c-Fos, NFATc1, c-Jun).
Main Results:
- Morusin treatment effectively prevented bone loss in the OVX-induced osteoporosis model.
- Morusin significantly inhibited RANKL-induced osteoclastogenesis *in vitro*.
- Morusin interfered with RANKL-activated signaling pathways and reduced the expression of critical osteoclast differentiation factors.
Conclusions:
- Morusin demonstrates a protective effect against OVX-induced bone loss.
- The findings suggest Morusin may be a viable therapeutic agent for postmenopausal osteoporosis.
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...